Literature DB >> 28536141

MELK and EZH2 Cooperate to Regulate Medulloblastoma Cancer Stem-like Cell Proliferation and Differentiation.

Hailong Liu1, Qianwen Sun2, Youliang Sun3, Junping Zhang1, Hongyu Yuan4, Shuhuan Pang5, Xueling Qi6, Haoran Wang1, Mingshan Zhang1, Hongwei Zhang1, Chunjiang Yu7, Chunyu Gu7.   

Abstract

Medulloblastoma is the most common malignant brain tumor in children. Although accumulated research has suggested that cancer stem-like cells play a key role in medulloblastoma tumorigenesis, the specific molecular mechanism regarding proliferation remains elusive. Here, we reported more abundant expression of maternal embryonic leucine-zipper kinase (MELK) and enhancer of zeste homolog 2 (EZH2) in medulloblastoma stem-like cells than in neural stem cells and the interaction between the two proteins could mediate the self-renewal of sonic hedgehog subtype medulloblastoma. In human medulloblastoma, extensive nodularity and large-cell/anaplastic subgroups differed according to the staining levels of MELK and EZH2 from the other two subgroups. The proportion of MELK- or EZH2-positive staining status could be considered as a potential indicator for survival. Mechanistically, MELK bound to and phosphorylated EZH2, and its methylation was induced by EZH2 in medulloblastoma, which could regulate the proliferation of cancer stem-like cells. In xenografts, loss of MELK or EZH2 attenuated medulloblastoma stem-like cell-derived tumor growth and promoted differentiation. These findings indicate that MELK-induced phosphorylation and EZH2-mediated methylation in MELK/EZH2 pathway are essential for medulloblastoma stem-like cell-derived tumor proliferation, thereby identifying a potential therapeutic strategy for these patients.Implications: This study demonstrates that the interaction occurring between MELK and EZH2 promotes self-proliferation and stemness, thus representing an attractive therapeutic target and potential candidate for diagnosis of medulloblastoma. Mol Cancer Res; 15(9); 1275-86. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28536141     DOI: 10.1158/1541-7786.MCR-17-0105

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  23 in total

1.  Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1.

Authors:  Lakshmi Reddy Bollu; Jonathan Shepherd; Dekuang Zhao; Yanxia Ma; William Tahaney; Corey Speers; Abhijit Mazumdar; Gordon B Mills; Powel H Brown
Journal:  NPJ Breast Cancer       Date:  2020-01-03

2.  Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.

Authors:  Alexandre Chlenski; Chanyoung Park; Marija Dobratic; Helen R Salwen; Brian Budke; Jae-Hyun Park; Ryan Miller; Mark A Applebaum; Emma Wilkinson; Yusuke Nakamura; Philip P Connell; Susan L Cohn
Journal:  Mol Cancer Ther       Date:  2019-01-23       Impact factor: 6.261

Review 3.  Epigenetic regulation in medulloblastoma.

Authors:  Jiaqing Yi; Jiang Wu
Journal:  Mol Cell Neurosci       Date:  2017-12-18       Impact factor: 4.314

4.  PRC2 Heterogeneity Drives Tumor Growth in Medulloblastoma.

Authors:  Jiaqing Yi; BongWoo Kim; Xuanming Shi; Xiaoming Zhan; Q Richard Lu; Zhenyu Xuan; Jiang Wu
Journal:  Cancer Res       Date:  2022-08-16       Impact factor: 13.312

5.  Necroptotic astrocytes contribute to maintaining stemness of disseminated medulloblastoma through CCL2 secretion.

Authors:  Hailong Liu; Youliang Sun; Jenny A O'Brien; Janusz Franco-Barraza; Xueling Qi; Hongyu Yuan; Wei Jin; Junping Zhang; Chunyu Gu; Zhenyu Zhao; Chunjiang Yu; Shiyu Feng; Xinguang Yu
Journal:  Neuro Oncol       Date:  2020-05-15       Impact factor: 12.300

6.  Identification of potential therapeutic targets in prostate cancer through a cross-species approach.

Authors:  Sarah Jurmeister; Antonio Ramos-Montoya; Chiranjeevi Sandi; Nelma Pértega-Gomes; Karan Wadhwa; Alastair D Lamb; Mark J Dunning; Jan Attig; Jason S Carroll; Lee Gd Fryer; Sérgio L Felisbino; David E Neal
Journal:  EMBO Mol Med       Date:  2018-03       Impact factor: 12.137

7.  Horizontal transfer of the stemness-related markers EZH2 and GLI1 by neuroblastoma-derived extracellular vesicles in stromal cells.

Authors:  Aranzazu Villasante; Amandine Godier-Furnemont; Alberto Hernandez-Barranco; Johanne Le Coq; Jasminka Boskovic; Hector Peinado; Jaume Mora; Josep Samitier; Gordana Vunjak-Novakovic
Journal:  Transl Res       Date:  2021-07-02       Impact factor: 10.171

8.  Challenges in validating candidate therapeutic targets in cancer.

Authors:  Jeffrey Settleman; Charles L Sawyers; Tony Hunter
Journal:  Elife       Date:  2018-02-08       Impact factor: 8.140

9.  Trimethylation of H3K27 during human cerebellar development in relation to medulloblastoma.

Authors:  Shahryar E Mir; Michiel Smits; Dennis Biesmans; Machteld Julsing; Marianna Bugiani; Eleonora Aronica; Gertjan J L Kaspers; Jacqueline Cloos; Thomas Würdinger; Esther Hulleman
Journal:  Oncotarget       Date:  2017-09-08

10.  RBM5-AS1 promotes radioresistance in medulloblastoma through stabilization of SIRT6 protein.

Authors:  Chuanying Zhu; Keke Li; Mawei Jiang; Siyu Chen
Journal:  Acta Neuropathol Commun       Date:  2021-07-05       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.